Free Trial
NASDAQ:ENTO

Entero Therapeutics (ENTO) Stock Price, News & Analysis

Entero Therapeutics logo
$0.63 +0.01 (+1.88%)
(As of 12/20/2024 05:31 PM ET)

About Entero Therapeutics Stock (NASDAQ:ENTO)

Key Stats

Today's Range
$0.57
$0.66
50-Day Range
$0.40
$0.80
52-Week Range
$0.19
$14.51
Volume
64,938 shs
Average Volume
359,216 shs
Market Capitalization
$3.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.

Entero Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
12th Percentile Overall Score

ENTO MarketRank™: 

Entero Therapeutics scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Entero Therapeutics.

  • Earnings Growth

    Earnings for Entero Therapeutics are expected to decrease in the coming year, from ($1.13) to ($1.52) per share.

  • Price to Book Value per Share Ratio

    Entero Therapeutics has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.47% of the float of Entero Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Entero Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Entero Therapeutics has recently decreased by 55.33%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Entero Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Entero Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.47% of the float of Entero Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Entero Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Entero Therapeutics has recently decreased by 55.33%, indicating that investor sentiment is improving significantly.
  • Search Interest

    3 people have searched for ENTO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Entero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $214.00 in company stock.

  • Percentage Held by Insiders

    Only 0.49% of the stock of Entero Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 12.30% of the stock of Entero Therapeutics is held by institutions.

  • Read more about Entero Therapeutics' insider trading history.
Receive ENTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ENTO Stock News Headlines

This is the worst sign for the U.S. stock market in 50 years
The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"
See More Headlines

ENTO Stock Analysis - Frequently Asked Questions

Entero Therapeutics' stock was trading at $2.94 at the beginning of the year. Since then, ENTO shares have decreased by 78.6% and is now trading at $0.63.
View the best growth stocks for 2024 here
.

Entero Therapeutics, Inc. (NASDAQ:ENTO) posted its quarterly earnings data on Monday, October, 21st. The company reported ($3.37) EPS for the quarter.

Shares of ENTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Entero Therapeutics investors own include Conduit Pharmaceuticals (CDT), BIOLASE (BIOL), Cyclacel Pharmaceuticals (CYCC), Daré Bioscience (DARE), Elevai Labs (ELAB), TRACON Pharmaceuticals (TCON) and Tempest Therapeutics (TPST).

Company Calendar

Last Earnings
10/21/2024
Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENTO
Previous Symbol
NASDAQ:ENTO
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

Net Income
$-15,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.31 per share

Miscellaneous

Free Float
4,731,000
Market Cap
$3.00 million
Optionable
N/A
Beta
1.15
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ENTO) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners